查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1858789

苯達莫司汀：全球市場佔有率和排名、總銷售額和需求預測（2025-2031 年）

Bendamustine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球苯達莫司汀市場規模預計為 4.16 億美元，預計到 2031 年將萎縮至 2.9 億美元，2025 年至 2031 年的複合年成長率為 -4.9%。

本報告對近期苯達莫司汀的關稅調整和國際策略反制措施進行了全面評估，評估內容包括跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組。

苯達莫司汀是一種化療藥物，用於治療慢性淋巴性白血病（CLL）、多發性骨髓瘤和非何傑金氏淋巴瘤。它是透過靜脈注射給藥。 2024年，全球苯達莫司汀產量達到約145萬單位，全球平均市場價格約為每單位287美元。

鑑於全球骨髓惡性腫瘤負擔日益加重以及人口老化，苯達莫司汀的市場前景極具吸引力。慢性淋巴性白血病(CLL)、非何傑金氏淋巴瘤(NHL) 和其他血液系統癌症發生率的不斷上升，推動了對有效且耐受性良好的化療藥物的需求——而這正是苯達莫司汀的優勢所在。許多國家的公共衛生和政府機構正在更新和擴展淋巴瘤和白血病治療指南，以促進含苯達莫司汀治療方法的採用和標準化。同時，聯合治療（化療合併標靶治療或免疫療法）的趨勢也在加速發展。苯達莫司汀的作用機制使其能夠與這些新型治療方法合併使用，從而拓展了新的適應症和治療方法。此外，非專利處方藥的出現和生命週期管理策略正在降低成本並提高藥物可近性，尤其是在醫療基礎設施正在發展的新興市場（亞太地區、拉丁美洲和東南亞）。

儘管有這些有利因素，苯達莫司汀仍面臨許多挑戰。首先，新型標靶治療和免疫療法，例如CAR-T細胞療法、單株抗體和小分子抑制劑，在治療指南和臨床實踐中日益佔據核心地位，這可能會在某些適應症中侵蝕苯達莫司汀的市場佔有率。其次，其副作用，包括骨髓抑制和感染風險，限制了其在體弱患者和合併其他疾病患者的應用。第三，不同市場的報銷、定價政策和法規環境差異顯著，嚴格的定價法規和有限的保險覆蓋範圍限制了其應用和盈利。第四，專利到期後非專利處方藥的競爭可能會降低利潤率。最後，在整個生產和供應鏈中保持品質、純度和合規性的一致性會帶來成本和營運風險。

下游臨床需求正轉向以精準治療、聯合治療和便利性為重點的治療模式。分子生物標記、基因定序和微量殘存疾病（MRD）監測等診斷技術的進步，使得早期療育和個體化治療成為可能，而苯達莫司汀擴大被考慮與免疫療法和標靶治療聯合應用於這些治療方法中。患者和醫療系統越來越重視療效與毒性、生活品質、給藥便利性、最佳化的治療方案以及成本效益高的副作用管理之間的平衡。新興市場對經濟實惠的學名藥和生物相似藥的需求強勁，而已開發市場則以新型聯合治療和指南推薦的治療方案為驅動力。門診、診所和居家照護環境的重要性日益凸顯，對苯達莫司汀的製劑、給藥方法和支持系統提出了更高的要求。

作為合成小分子藥物，苯達莫司汀依賴上游工程原料，包括烷化劑中間體、嘌呤類似物中間體、有機化學試劑、高純度溶劑以及純化和結晶過程中使用的中間體。甲醇烷基化部分可來自氯代有機化合物、環烷基或氮丙啶/環狀結構前驅物。嘌呤類似物部分需要核苷或核鹼基前驅物、催化劑、立體化學控制以及極低的雜質含量。高純度溶劑、金屬催化劑或還原劑/氧化劑必不可少，並且需要嚴格控制殘留金屬和副產物。供應穩定性受化學中間體或精細化學品生產商的產能、環境法規（特別是關於有機溶劑排放和廢棄物處理的法規）、貿易和進出口政策以及特定合成路線的專利保護或獨佔權的影響。合成、純化、結晶和中間體處理過程中的品管對於最終藥物的穩定性、安全性和監管核准至關重要。該產品的毛利率約為 80%。

本報告旨在按地區/國家、類型和應用程式對全球苯達莫司汀市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

苯達莫司汀市場規模、估算和預測以銷售（千）和收入（百萬美元）為單位呈現，基準年為2024年，並包含2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定苯達莫司汀的業務/成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Teva
  • Eisai
  • Eagle Pharmaceuticals
  • MundiPharma
  • Viatris
  • Apotex
  • Emcure
  • Miracalus Pharma
  • Fresenius
  • Zhengda Tianqing
  • Slayback Pharma
  • SYMBIO SEIYAKU
  • Hikma Pharmaceuticals
  • Natco Pharma
  • Medac GmbH

按類型分類的細分市場

  • 25毫克注射液
  • 100毫克注射液
  • 其他

應用領域

  • 慢性淋巴性白血病
  • 多發性骨髓瘤
  • 非何傑金氏淋巴瘤

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Bendamustine was estimated to be worth US$ 416 million in 2024 and is forecast to a readjusted size of US$ 290 million by 2031 with a CAGR of -4.9% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Bendamustine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.In 2024, global Bendamustine production reached approximately 1.45 m units, with an average global market price of around US$ 287 perunit.

In the face of a rising global burden of hematologic malignancies and the aging population, the opportunity for bendamustine is highly compelling. Incidence increases in chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and other blood cancers create rising demand for chemotherapy agents that combine efficacy with tolerability-exactly where bendamustine shines. Public health bodies and governmental agencies in many countries have updated or expanded treatment guidelines for lymphomas and leukemia, which boosts adoption and standardization of treatments incorporating bendamustine. In parallel, the movement toward combination regimens (chemotherapy plus targeted or immunotherapy) is accelerating; bendamustine's mechanism allows it to pair with these newer modalities, opening up new indication and regimen expansion. Further, the arrival of generics and lifecycle management strategies reduces cost and increases access, especially in emerging markets (Asia-Pacific, Latin America, Southeast Asia) with improving healthcare infrastructure.

Despite strong tailwinds, bendamustine faces significant challenges. First, novel targeted therapies and immunotherapies-such as CAR-T cell therapy, monoclonal antibodies, and small molecule inhibitors-are increasingly taking center stage in treatment guidelines and clinical practice, which can erode bendamustine's share in some indications. Second, adverse effect profiles-bone-marrow suppression, infection risk, etc.-limit its use in frail patients or those with comorbidities. Third, reimbursement, pricing policies and regulatory environments vary widely; in markets with strict price regulation or limited insurance coverage, uptake and profitability are constrained. Fourth, competition from generics post-patent expiry can drive down margins. Finally, maintaining consistent quality, purity and regulatory compliance across manufacturing and supply chain presents both cost and operational risks.

On the downstream side, clinical demand is shifting toward more precise, combination, and convenience-oriented treatment paradigms. Advances in diagnostic technologies-molecular biomarkers, gene sequencing, minimal residual disease (MRD) monitoring-enable earlier intervention and more tailored therapy; bendamustine, when combined with immunotherapy or targeted agents, is increasingly considered in such regimens. Patients and health systems are placing growing importance on the balance between efficacy and toxicity, quality of life, administration convenience, treatment schedule improvements, and the cost of managing side effects. Markets in emerging economies display strong demand for cost-effective, generic or biosimilar versions; in developed markets, newer combinations or recommended regimens (per guidelines) lead the adoption. Outpatient, clinic-based, or home care settings are also increasingly relevant, imposing higher demands on formulation, delivery, and support of bendamustine products.

Bendamustine, as a synthetic small molecule drug, depends upstream on raw materials including alkylating-agent intermediates, purine analog intermediate building blocks, organic chemical reagents, high-purity solvents, and intermediates used in purification and crystallization steps. The alkylating portion may derive from chloro-organic compounds, cyclic alkyl or aziridine / cyclic moiety precursors; the purine analog side requires nucleoside or nucleobase precursors, catalysts, stereo-chemistry control, and minimal impurities. High-purity solvents, metal catalysts or reducing/oxidizing agents are essential, with tight control over residual metals and by-products. Supply stability is influenced by capacity at chemical intermediates or fine chemicals manufacturers, environmental regulation (especially around organic solvent emissions and waste handling), trade and import/export policies, and patent protections or exclusivity in certain synthetic routes. Quality control in the synthesis, purification, crystallization, and intermediate handling steps is critical for final drug stability, safety, and regulatory approval.The gross profit margin of this product is around 80%.

This report aims to provide a comprehensive presentation of the global market for Bendamustine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Bendamustine by region & country, by Type, and by Application.

The Bendamustine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bendamustine.

Market Segmentation

By Company

  • Teva
  • Eisai
  • Eagle Pharmaceuticals
  • MundiPharma
  • Viatris
  • Apotex
  • Emcure
  • Miracalus Pharma
  • Fresenius
  • Zhengda Tianqing
  • Slayback Pharma
  • SYMBIO SEIYAKU
  • Hikma Pharmaceuticals
  • Natco Pharma
  • Medac GmbH

Segment by Type

  • 25mg Injection
  • 100mg Injection
  • Others

Segment by Application

  • Chronic Lymphocytic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Bendamustine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Bendamustine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Bendamustine in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Bendamustine Product Introduction
  • 1.2 Global Bendamustine Market Size Forecast
    • 1.2.1 Global Bendamustine Sales Value (2020-2031)
    • 1.2.2 Global Bendamustine Sales Volume (2020-2031)
    • 1.2.3 Global Bendamustine Sales Price (2020-2031)
  • 1.3 Bendamustine Market Trends & Drivers
    • 1.3.1 Bendamustine Industry Trends
    • 1.3.2 Bendamustine Market Drivers & Opportunity
    • 1.3.3 Bendamustine Market Challenges
    • 1.3.4 Bendamustine Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Bendamustine Players Revenue Ranking (2024)
  • 2.2 Global Bendamustine Revenue by Company (2020-2025)
  • 2.3 Global Bendamustine Players Sales Volume Ranking (2024)
  • 2.4 Global Bendamustine Sales Volume by Company Players (2020-2025)
  • 2.5 Global Bendamustine Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Bendamustine Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Bendamustine Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Bendamustine
  • 2.9 Bendamustine Market Competitive Analysis
    • 2.9.1 Bendamustine Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Bendamustine Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bendamustine as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 25mg Injection
    • 3.1.2 100mg Injection
    • 3.1.3 Others
  • 3.2 Global Bendamustine Sales Value by Type
    • 3.2.1 Global Bendamustine Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Bendamustine Sales Value, by Type (2020-2031)
    • 3.2.3 Global Bendamustine Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Bendamustine Sales Volume by Type
    • 3.3.1 Global Bendamustine Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Bendamustine Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Bendamustine Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Bendamustine Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Chronic Lymphocytic Leukemia
    • 4.1.2 Multiple Myeloma
    • 4.1.3 Non-Hodgkin's Lymphoma
  • 4.2 Global Bendamustine Sales Value by Application
    • 4.2.1 Global Bendamustine Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Bendamustine Sales Value, by Application (2020-2031)
    • 4.2.3 Global Bendamustine Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Bendamustine Sales Volume by Application
    • 4.3.1 Global Bendamustine Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Bendamustine Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Bendamustine Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Bendamustine Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Bendamustine Sales Value by Region
    • 5.1.1 Global Bendamustine Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Bendamustine Sales Value by Region (2020-2025)
    • 5.1.3 Global Bendamustine Sales Value by Region (2026-2031)
    • 5.1.4 Global Bendamustine Sales Value by Region (%), (2020-2031)
  • 5.2 Global Bendamustine Sales Volume by Region
    • 5.2.1 Global Bendamustine Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Bendamustine Sales Volume by Region (2020-2025)
    • 5.2.3 Global Bendamustine Sales Volume by Region (2026-2031)
    • 5.2.4 Global Bendamustine Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Bendamustine Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Bendamustine Sales Value, 2020-2031
    • 5.4.2 North America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Bendamustine Sales Value, 2020-2031
    • 5.5.2 Europe Bendamustine Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Bendamustine Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Bendamustine Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Bendamustine Sales Value, 2020-2031
    • 5.7.2 South America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Bendamustine Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Bendamustine Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Bendamustine Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Bendamustine Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Bendamustine Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Bendamustine Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Bendamustine Sales Value, 2020-2031
    • 6.3.2 United States Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Bendamustine Sales Value, 2020-2031
    • 6.4.2 Europe Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Bendamustine Sales Value, 2020-2031
    • 6.5.2 China Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Bendamustine Sales Value, 2020-2031
    • 6.6.2 Japan Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Bendamustine Sales Value, 2020-2031
    • 6.7.2 South Korea Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Bendamustine Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Bendamustine Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Bendamustine Sales Value, 2020-2031
    • 6.9.2 India Bendamustine Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Bendamustine Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Teva
    • 7.1.1 Teva Company Information
    • 7.1.2 Teva Introduction and Business Overview
    • 7.1.3 Teva Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Teva Bendamustine Product Offerings
    • 7.1.5 Teva Recent Development
  • 7.2 Eisai
    • 7.2.1 Eisai Company Information
    • 7.2.2 Eisai Introduction and Business Overview
    • 7.2.3 Eisai Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Eisai Bendamustine Product Offerings
    • 7.2.5 Eisai Recent Development
  • 7.3 Eagle Pharmaceuticals
    • 7.3.1 Eagle Pharmaceuticals Company Information
    • 7.3.2 Eagle Pharmaceuticals Introduction and Business Overview
    • 7.3.3 Eagle Pharmaceuticals Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Eagle Pharmaceuticals Bendamustine Product Offerings
    • 7.3.5 Eagle Pharmaceuticals Recent Development
  • 7.4 MundiPharma
    • 7.4.1 MundiPharma Company Information
    • 7.4.2 MundiPharma Introduction and Business Overview
    • 7.4.3 MundiPharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 MundiPharma Bendamustine Product Offerings
    • 7.4.5 MundiPharma Recent Development
  • 7.5 Viatris
    • 7.5.1 Viatris Company Information
    • 7.5.2 Viatris Introduction and Business Overview
    • 7.5.3 Viatris Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 Viatris Bendamustine Product Offerings
    • 7.5.5 Viatris Recent Development
  • 7.6 Apotex
    • 7.6.1 Apotex Company Information
    • 7.6.2 Apotex Introduction and Business Overview
    • 7.6.3 Apotex Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Apotex Bendamustine Product Offerings
    • 7.6.5 Apotex Recent Development
  • 7.7 Emcure
    • 7.7.1 Emcure Company Information
    • 7.7.2 Emcure Introduction and Business Overview
    • 7.7.3 Emcure Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Emcure Bendamustine Product Offerings
    • 7.7.5 Emcure Recent Development
  • 7.8 Miracalus Pharma
    • 7.8.1 Miracalus Pharma Company Information
    • 7.8.2 Miracalus Pharma Introduction and Business Overview
    • 7.8.3 Miracalus Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Miracalus Pharma Bendamustine Product Offerings
    • 7.8.5 Miracalus Pharma Recent Development
  • 7.9 Fresenius
    • 7.9.1 Fresenius Company Information
    • 7.9.2 Fresenius Introduction and Business Overview
    • 7.9.3 Fresenius Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Fresenius Bendamustine Product Offerings
    • 7.9.5 Fresenius Recent Development
  • 7.10 Zhengda Tianqing
    • 7.10.1 Zhengda Tianqing Company Information
    • 7.10.2 Zhengda Tianqing Introduction and Business Overview
    • 7.10.3 Zhengda Tianqing Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Zhengda Tianqing Bendamustine Product Offerings
    • 7.10.5 Zhengda Tianqing Recent Development
  • 7.11 Slayback Pharma
    • 7.11.1 Slayback Pharma Company Information
    • 7.11.2 Slayback Pharma Introduction and Business Overview
    • 7.11.3 Slayback Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Slayback Pharma Bendamustine Product Offerings
    • 7.11.5 Slayback Pharma Recent Development
  • 7.12 SYMBIO SEIYAKU
    • 7.12.1 SYMBIO SEIYAKU Company Information
    • 7.12.2 SYMBIO SEIYAKU Introduction and Business Overview
    • 7.12.3 SYMBIO SEIYAKU Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 SYMBIO SEIYAKU Bendamustine Product Offerings
    • 7.12.5 SYMBIO SEIYAKU Recent Development
  • 7.13 Hikma Pharmaceuticals
    • 7.13.1 Hikma Pharmaceuticals Company Information
    • 7.13.2 Hikma Pharmaceuticals Introduction and Business Overview
    • 7.13.3 Hikma Pharmaceuticals Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 Hikma Pharmaceuticals Bendamustine Product Offerings
    • 7.13.5 Hikma Pharmaceuticals Recent Development
  • 7.14 Natco Pharma
    • 7.14.1 Natco Pharma Company Information
    • 7.14.2 Natco Pharma Introduction and Business Overview
    • 7.14.3 Natco Pharma Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.14.4 Natco Pharma Bendamustine Product Offerings
    • 7.14.5 Natco Pharma Recent Development
  • 7.15 Medac GmbH
    • 7.15.1 Medac GmbH Company Information
    • 7.15.2 Medac GmbH Introduction and Business Overview
    • 7.15.3 Medac GmbH Bendamustine Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.15.4 Medac GmbH Bendamustine Product Offerings
    • 7.15.5 Medac GmbH Recent Development

8 Industry Chain Analysis

  • 8.1 Bendamustine Industrial Chain
  • 8.2 Bendamustine Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Bendamustine Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Bendamustine Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Bendamustine Market Trends
  • Table 2. Bendamustine Market Drivers & Opportunity
  • Table 3. Bendamustine Market Challenges
  • Table 4. Bendamustine Market Restraints
  • Table 5. Global Bendamustine Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Bendamustine Revenue Market Share by Company (2020-2025)
  • Table 7. Global Bendamustine Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Bendamustine Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Bendamustine Price by Company (2020-2025) & (USD/Unit)
  • Table 10. Key Manufacturers Bendamustine Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Bendamustine Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Bendamustine
  • Table 13. Global Bendamustine Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bendamustine as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Bendamustine Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Bendamustine Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Bendamustine Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Bendamustine Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Bendamustine Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Bendamustine Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Bendamustine Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Bendamustine Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Bendamustine Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Bendamustine Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Bendamustine Price by Type (2020-2025) & (USD/Unit)
  • Table 27. Global Bendamustine Price by Type (2026-2031) & (USD/Unit)
  • Table 28. Global Bendamustine Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Bendamustine Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Bendamustine Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Bendamustine Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Bendamustine Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Bendamustine Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Bendamustine Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Bendamustine Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Bendamustine Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Bendamustine Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Bendamustine Price by Application (2020-2025) & (USD/Unit)
  • Table 39. Global Bendamustine Price by Application (2026-2031) & (USD/Unit)
  • Table 40. Global Bendamustine Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Bendamustine Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Bendamustine Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Bendamustine Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Bendamustine Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Bendamustine Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Bendamustine Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Bendamustine Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Bendamustine Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Bendamustine Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Bendamustine Average Price by Region (2020-2025) & (USD/Unit)
  • Table 51. Global Bendamustine Average Price by Region (2026-2031) & (USD/Unit)
  • Table 52. Key Countries/Regions Bendamustine Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Bendamustine Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Bendamustine Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Bendamustine Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Bendamustine Sales Volume, (2026-2031) & (K Units)
  • Table 57. Teva Company Information
  • Table 58. Teva Introduction and Business Overview
  • Table 59. Teva Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 60. Teva Bendamustine Product Offerings
  • Table 61. Teva Recent Development
  • Table 62. Eisai Company Information
  • Table 63. Eisai Introduction and Business Overview
  • Table 64. Eisai Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 65. Eisai Bendamustine Product Offerings
  • Table 66. Eisai Recent Development
  • Table 67. Eagle Pharmaceuticals Company Information
  • Table 68. Eagle Pharmaceuticals Introduction and Business Overview
  • Table 69. Eagle Pharmaceuticals Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 70. Eagle Pharmaceuticals Bendamustine Product Offerings
  • Table 71. Eagle Pharmaceuticals Recent Development
  • Table 72. MundiPharma Company Information
  • Table 73. MundiPharma Introduction and Business Overview
  • Table 74. MundiPharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 75. MundiPharma Bendamustine Product Offerings
  • Table 76. MundiPharma Recent Development
  • Table 77. Viatris Company Information
  • Table 78. Viatris Introduction and Business Overview
  • Table 79. Viatris Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 80. Viatris Bendamustine Product Offerings
  • Table 81. Viatris Recent Development
  • Table 82. Apotex Company Information
  • Table 83. Apotex Introduction and Business Overview
  • Table 84. Apotex Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 85. Apotex Bendamustine Product Offerings
  • Table 86. Apotex Recent Development
  • Table 87. Emcure Company Information
  • Table 88. Emcure Introduction and Business Overview
  • Table 89. Emcure Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 90. Emcure Bendamustine Product Offerings
  • Table 91. Emcure Recent Development
  • Table 92. Miracalus Pharma Company Information
  • Table 93. Miracalus Pharma Introduction and Business Overview
  • Table 94. Miracalus Pharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 95. Miracalus Pharma Bendamustine Product Offerings
  • Table 96. Miracalus Pharma Recent Development
  • Table 97. Fresenius Company Information
  • Table 98. Fresenius Introduction and Business Overview
  • Table 99. Fresenius Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 100. Fresenius Bendamustine Product Offerings
  • Table 101. Fresenius Recent Development
  • Table 102. Zhengda Tianqing Company Information
  • Table 103. Zhengda Tianqing Introduction and Business Overview
  • Table 104. Zhengda Tianqing Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 105. Zhengda Tianqing Bendamustine Product Offerings
  • Table 106. Zhengda Tianqing Recent Development
  • Table 107. Slayback Pharma Company Information
  • Table 108. Slayback Pharma Introduction and Business Overview
  • Table 109. Slayback Pharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 110. Slayback Pharma Bendamustine Product Offerings
  • Table 111. Slayback Pharma Recent Development
  • Table 112. SYMBIO SEIYAKU Company Information
  • Table 113. SYMBIO SEIYAKU Introduction and Business Overview
  • Table 114. SYMBIO SEIYAKU Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 115. SYMBIO SEIYAKU Bendamustine Product Offerings
  • Table 116. SYMBIO SEIYAKU Recent Development
  • Table 117. Hikma Pharmaceuticals Company Information
  • Table 118. Hikma Pharmaceuticals Introduction and Business Overview
  • Table 119. Hikma Pharmaceuticals Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 120. Hikma Pharmaceuticals Bendamustine Product Offerings
  • Table 121. Hikma Pharmaceuticals Recent Development
  • Table 122. Natco Pharma Company Information
  • Table 123. Natco Pharma Introduction and Business Overview
  • Table 124. Natco Pharma Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 125. Natco Pharma Bendamustine Product Offerings
  • Table 126. Natco Pharma Recent Development
  • Table 127. Medac GmbH Company Information
  • Table 128. Medac GmbH Introduction and Business Overview
  • Table 129. Medac GmbH Bendamustine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
  • Table 130. Medac GmbH Bendamustine Product Offerings
  • Table 131. Medac GmbH Recent Development
  • Table 132. Key Raw Materials Lists
  • Table 133. Raw Materials Key Suppliers Lists
  • Table 134. Bendamustine Downstream Customers
  • Table 135. Bendamustine Distributors List
  • Table 136. Research Programs/Design for This Report
  • Table 137. Key Data Information from Secondary Sources
  • Table 138. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Bendamustine Product Picture
  • Figure 2. Global Bendamustine Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Bendamustine Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Bendamustine Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Bendamustine Sales Price (2020-2031) & (USD/Unit)
  • Figure 6. Bendamustine Report Years Considered
  • Figure 7. Global Bendamustine Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Bendamustine Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Bendamustine Revenue in 2024
  • Figure 10. Bendamustine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. 25mg Injection Picture
  • Figure 12. 100mg Injection Picture
  • Figure 13. Others Picture
  • Figure 14. Global Bendamustine Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Bendamustine Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Bendamustine Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 17. Global Bendamustine Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Bendamustine Price by Type (2020-2031) & (USD/Unit)
  • Figure 19. Product Picture of Chronic Lymphocytic Leukemia
  • Figure 20. Product Picture of Multiple Myeloma
  • Figure 21. Product Picture of Non-Hodgkin's Lymphoma
  • Figure 22. Global Bendamustine Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 23. Global Bendamustine Sales Value Market Share by Application, 2024 & 2031
  • Figure 24. Global Bendamustine Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 25. Global Bendamustine Sales Volume Market Share by Application, 2024 & 2031
  • Figure 26. Global Bendamustine Price by Application (2020-2031) & (USD/Unit)
  • Figure 27. North America Bendamustine Sales Value (2020-2031) & (US$ Million)
  • Figure 28. North America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Europe Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. Europe Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 31. Asia Pacific Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. Asia Pacific Bendamustine Sales Value by Region (%), 2024 VS 2031
  • Figure 33. South America Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. South America Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 35. Middle East & Africa Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. Middle East & Africa Bendamustine Sales Value by Country (%), 2024 VS 2031
  • Figure 37. Key Countries/Regions Bendamustine Sales Value (%), (2020-2031)
  • Figure 38. Key Countries/Regions Bendamustine Sales Volume (%), (2020-2031)
  • Figure 39. United States Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. United States Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 41. United States Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Europe Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Europe Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Europe Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 45. China Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. China Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 47. China Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Japan Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. Japan Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 50. Japan Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 51. South Korea Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 52. South Korea Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 53. South Korea Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 54. Southeast Asia Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 55. Southeast Asia Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 56. Southeast Asia Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 57. India Bendamustine Sales Value, (2020-2031) & (US$ Million)
  • Figure 58. India Bendamustine Sales Value by Type (%), 2024 VS 2031
  • Figure 59. India Bendamustine Sales Value by Application (%), 2024 VS 2031
  • Figure 60. Bendamustine Industrial Chain
  • Figure 61. Bendamustine Manufacturing Cost Structure
  • Figure 62. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 63. Bottom-up and Top-down Approaches for This Report
  • Figure 64. Data Triangulation
  • Figure 65. Key Executives Interviewed